Birkenmaier, Ion
Maul, Lara Valeska
Oyanguren, Iker
Sorbe, Christina
Fröhlich, Fabienne
Schlapbach, Christoph
Heidemeyer, Kristine
Yawalkar, Nikhil
Boehncke, Wolf-Henning
Ring, Hans-Christian
Thyssen, Jacob P.
Egeberg, Alexander
Micheroli, Raphael
Thomsen, Simon Francis
Mainetti, Carlo
Cozzio, Antonio
Kündig, Thomas M.
Levesque, Mitchell P.
Navarini, Alexander
Maul, Julia-Tatjana
Funding for this research was provided by:
University Hospital of Zurich, Switzerland
University of Zurich
Article History
Received: 30 July 2024
Revised: 2 August 2024
Accepted: 3 September 2024
First Online: 1 October 2024
Declarations
:
: IB: is an employee of the University Hospital of Zürich and PhD candidate at the University of Zürich and has declared no conflict of interest. LVM: Outside of the submitted work, LVM has served as advisor and/or received speaking fees and/or grants and/or participated in clinical trials sponsored by Almirall, Amgen, BMS, Canfield, Eli Lilly, Incyte, MSD, Novartis, Pierre Fabre, Roche, and Sanofi. CSor: has declared no conflict of interest. IO: has declared no conflict of interest. FF: Unrelated to this project FF has received speaking fees from Eli Lilly. CSchla: With no relation to the present manuscript, Prof. Schlapbach has received honoraria as adviser or speaker for Abbvie, Almirall, BMS, Incyte, LEO Pharma, Lilly, Kiowa Kirin, Novartis, Pfizer and Sanofi and has received research funding from PPM Services. KH: With no relation to the present manuscript, KH has been an advisor for and/or has received research support from Abbvie, Almirall, Galderma, Sanofi, UCB. NY: Outside of the submitted work, NY has served as advisor and/or received speaking fees and/or grants and/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Galderma, LEO Pharma, Janssen-Cilag, MSD, Novartis, Pfizer, Sanofi-Genzyme, UCB. WHB: has received honoraria as a speaker and/or consultant from Abbvie, Almirall, Amgen, BMS, Janssen, Leo, Lilly, Novartis and UCB. HCR: Dr. Ring has received support for attending meeting from Pfizer Inc. JPT: Outside of the submitted work Prof. Thyssen has been an advisor for AbbVie, Almirall, Arena Pharmaceuticals, Coloplast, OM Pharma, Aslan Pharmaceuticals, Union Therapeutics, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron, and Sanofi-Genzyme, a speaker for AbbVie, Almirall, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron, and Sanofi-Genzyme, and received research grants from Pfizer, Regeneron, and Sanofi-Genzyme. Prof. Thyssen is currently employed by LEO Pharma. AE: Outside of the submitted work, Prof. Egeberg has received research funding from Almirall, Pfizer, Eli Lilly, Novartis, Bristol-Myers Squibb, AbbVie, Janssen Pharmaceuticals, Boehringer Ingelheim, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and/or speaker from Amgen, AbbVie, Almirall, Leo Pharma, Zuellig Pharma Ltd., Galápagos NV, Sun Pharmaceuticals, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Union Therapeutics, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb, McNeil Consumer Healthcare, Horizon Therapeutics, Boehringer Ingelheim, and Janssen Pharmaceuticals, and is currently employed by LEO Pharma. RM: has declared no conflict of interest. SFT: has been a speaker and/or advisor for and/or has received research support from Abbvie, Almirall, Eli Lilly, Galderma, Incyte, Janssen, Leo Pharma, Novartis, Pfizer, Sanofi, Symphogen, UCB, and Union therapeutics. CM: Advisory activities outside of the submitted work for AbbVie, Celgene, Eli-Lilly, Galderma, Sanofi and Novartis. AC: Advisory activities outside of the submitted work for AbbVie, Almirall, Amgen, Galderma, Leo Pharma, Janssen-Cilag, Novartis and UCB. TK: has intermittent, project focused consulting and/or advisory relationships with Leo Pharma, Janssen-Cilag, Eli Lilly, Pierre Fabre, Sanofi-Genzyme, Abbvie, Biomed AG, Novartis, Almirall, Bristol-Myers Squibb, Galderma, L’Oréal/LaRoche-Posay, Merck-Sharp & Dohme, Zur Rose AG, Allergy Therapeutics AG, Derma2go AG, Oncobit AG, EVAX AG, Saiba Biotechnology AG, Saiba Animal Health AG, AltiBio Corp, Encoded Corp, Mabylon AG, MannKind Corp and XBiotech Corp. MPL: has declared no conflict of interest. AAN: declares being a consultant and advisor and/or receiving speaking fees and/or grants and/or served as an investigator in clinical trials for AbbVie, Almirall, Amgen, Biomed, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, GlaxoSmithKline, LEO Pharma, Louis-Widmer AG, Janssen-Cilag, MSD, Novartis, Pfizer, Pierre Fabre Pharma, Regeneron, Sandoz, Sanofi and UCB. JTM: has served as advisor and/or received speaking fees and/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, BMS, Celgene, Eli Lilly, Incyte, LEO Pharma, Janssen-Cilag, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi, UCB.
: This research was approved by the University Hospital of Zürich review board. The SDNTT registry is approved by the Ethics Committee Northwest and Central Switzerland (EKNZ 62/11) and conducted in accordance with the declaration of Helsinki. The registry is registered with the ClinicalTrials.gov ID NCT01706692.
: Basic tools were used to improve vocabulary and grammar. No AI, language model, machine learning, or similar technologies were used in the creation or editing of any of the content in this submission. All content is unique and original.
: All patients recruited into the SDNTT registry gave their informed consent.